scholarly journals Clinical significance of extranodal extension in sentinel lymph node positive breast cancers

2020 ◽  
Author(s):  
Xia Yang ◽  
Xiaoxi Ma ◽  
Wentao Yang ◽  
Ruohong Shui
Keyword(s):  
Breast Cancer ◽  
Regression Analysis ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Prognostic Value ◽  
Breast Cancers ◽  
Univariable Analysis ◽  
Positive Ratio ◽  
Extranodal Extension ◽  
Cutoff Values

Abstract Background The precise stage of lymph node (LN) metastasis is a strong prognostic factor in breast cancer, and sentinel lymph node (SLN) is the first station of nodal metastasis, whereas the clinical value of extranodal extension (ENE) in SLN are still in exploration.Objective Our study aimed to evaluate the predictive and prognostic values of ENE in SLN and to investigate the feasibility of ENE to predict non-SLN metastasis, disease free survival (DFS) and overall survival (OS) in clinical practice.Methods 183 cases of primary invasive breast cancer (cT1-2N0 breast cancer with 1-2 positive SLNs) underwent SLN biopsy and axillary lymph node dissection (ALND) between 2008 and 2015 were extracted from the pathology database of Fudan University Shanghai Cancer Center. Sections were reviewed for the microscopic features of SLN, including the number and pattern of SLN metastasis, SLNs positive ratio, nodal vascular invasion (NVI), and ENE. The associations between tumor features including ENE and non-SLN metastasis, DFS and OS were analyzed. Moreover, ENE was subclassified into circumferential (CD-ENE) and perpendicular (PD-ENE) and set a threshold as 2mm or 3mm to evaluate the prognostic value of ENE.Results 73/183 (39.9 %) cases were positive for ENE in SLN. Logistic regression analysis indicated that ENE, the number and pattern of SLN involvement, SLN positive ratio, and NVI were significantly associated with the presence of non-SLN metastasis in univariate analysis. ENE, higher number of SLN involvement, SLN macrometastasis, and NVI were significantly associated with a higher rate of non-SLN metastasis in multivariate analysis. Cox regression analysis showed ENE in SLN was associated with DFS and OS in univariable analysis, but not in multivariable analysis. Whereas the size of ENE (CD-ENE and PD-ENE) subdivided by 3mm (or 2mm) cutoff values were not found as strongly prognostic factors of DFS and OS as well.Conclusions Our study indicated that ENE in SLN was a predictor for non-SLN metastasis in breast cancers, patients with ENE in SLN had a higher rate of non-SLN metastasis. ENE in SLN was associated with DFS and OS in univariable analysis, but not in multivariable analysis. The size of ENE (CD-ENE and PD-ENE) which was classified by a 3mm (or 2mm) cutoff value had no significant prognostic values in this study. The prognostic value of ENE in SLN and the cutoff values of ENE in SLN in breast cancers need further investigation.

scholarly journals Clinical significance of extranodal extension in sentinel lymph node positive breast cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Xia Yang ◽  
XiaoXi Ma ◽  
Wentao Yang ◽  
Ruohong Shui
Keyword(s):  
Breast Cancer ◽  
Regression Analysis ◽  
Lymph Node ◽  
Cox Regression ◽  
Rank Test ◽  
Breast Cancers ◽  
Cox Regression Analysis ◽  
Extranodal Extension ◽  
Kaplan Meier ◽  
Nodal Burden

Abstract The precise stage of lymph node (LN) metastasis is a strong prognostic factor in breast cancers, and sentinel lymph node (SLN) is the first station of nodal metastasis. A number of patients have extranodal extension (ENE) in SLN, whereas the clinical values of ENE in SLN in breast cancers are still in exploration. The aim of our study was to evaluate the predictive and prognostic values of ENE in SLN in breast cancers, and to investigate the feasibility of ENE to predict non-SLN metastasis, nodal burden, disease free survival (DFS) and overall survival (OS) in clinical practice. 266 cases of primary invasive breast cancer (cT1-2N0 breast cancer) underwent SLN biopsy and axillary lymph node dissection (ALND) between 2008 and 2015 were extracted from the pathology database of Fudan University Shanghai Cancer Center. ENE in SLN was defined as extension of neoplastic cells through the lymph-nodal capsule into the peri-nodal adipose tissue, and was classified as no larger than 2 mm and larger than 2 mm group. The associations between ENE and clinicopathological features, non-SLN metastasis, nodal burden, DFS, and OS were analyzed. In the 266 patients with involved SLN, 100(37.6%) were positive for ENE in SLN. 67 (25.2%) cases had ENE no larger than 2 mm in diameter, and 33(12.4%) had ENE larger than 2 mm. Among the clinicopathological characteristics, the presence of ENE in SLN was associated with higher pT and pN stages, PR status, lympho-vascular invasion. Logistic regression analysis indicated that patients with ENE in SLN had higher rate of non-SLN metastasis (OR4.80, 95% CI 2.47–9.34, P < 0.001). Meanwhile, in patients with SLN micrometastasis or 1–2 SLNs involvement, ENE positive patients had higher rate of non-SLN metastasis, comparing with ENE negative patients (P < 0.001, P = 0.004 respectively). The presence of ENE in SLN was correlated with nodal burden, including the pattern and number of involved SLN (P < 0.001, P < 0.001 respectively), the number of involved non-SLN and total positive LNs (P < 0.001, P < 0.001 respectively). Patients with ENE had significantly higher frequency of pN2 disease (P < 0.001). For the disease recurrence and survival status, Cox regression analysis showed that patients with ENE in SLN had significantly reduced DFS (HR 3.05, 95%CI 1.13–10.48, P = 0.008) and OS (HR 3.34, 95%CI 0.74–14.52, P = 0.092) in multivariate analysis. Kaplan–Meier curves and log-rank test showed that patients with ENE in SLN had lower DFS and OS (for DFS: P < 0.001; and for OS: P < 0.001 respectively). Whereas no significant difference was found in nodal burden between ENE ≤ 2 mm and > 2 mm groups, except the number of SLN metastasis was higher in patients with ENE > 2 mm. Cox regression analysis, Kaplan–Meier curves and log-rank test indicated that the size of ENE was not an independent factor of DFS and OS. Our study indicated that ENE in SLN was a predictor for non-SLN metastasis, nodal burden and prognosis in breast cancers. Patients with ENE in SLN had a higher rate of non-SLN metastasis, higher frequency of pN2 disease, and poorer prognosis. Patients with ENE in SLN may benefit from additional ALND, even in SLN micrometastasis or 1–2 SLNs involvement patients. The presence of ENE in SLN should be evaluated in clinical practice. Size of ENE which was classified by a 2 mm cutoff value had no significant predictive and prognostic values in this study. The cutoff values of ENE in SLN need further investigation.

Extranodal Extension on Sentinel Lymph Node Dissection: Why should we Treat it Differently?

2014 ◽  
Vol 80 (10) ◽  
pp. 932-935 ◽  
Author(s):  
Audrey H. Choi ◽  
Matthew Surrusco ◽  
Samuel Rodriguez ◽  
Khaled Bahjri ◽  
Naveen Solomon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Node Dissection ◽  
Disease Recurrence ◽  
Sentinel Lymph Node Dissection ◽  
Axillary Lymph ◽  
Node Dissection ◽  
Extranodal Extension ◽  
Overall Mortality

American College of Surgeons Oncology Group Z0011 concluded that axillary lymph node dissection (ALND) may be avoided in selected patients with breast cancer with limited axillary nodal metastasis on sentinel lymph node dissection (SLND). However, patients with extranodal extension (ENE) were excluded to the follow existing standard of care, which is completion ALND. The significance of ENE detected on SLND is not well defined. Our objective was to determine the impact of ENE found on SLND on nonsentinel lymph node (NSLN) metastasis, recurrence, and overall mortality. We evaluated patients with breast cancer treated at a tertiary cancer center from 2005 to 2012. SLND was performed in 655 patients. Of those, 478 of 655 (73.0%) patients had no SLN metastases, 124 of 655 (18.9%) had SLN metastases without ENE (SLN-ENE), and 53 of 655 (8.1%) had SLN metastases with ENE (SLN1ENE). Of patients undergoing ALND, NSLN metastasis was detected in 37 of 84 (44.0%) of patients in the SLN-ENE group and 26 of 45 (57.8%) patients in the SLN1ENE group ( P = 0.14). On adjusted analyses, ENE was associated with increased disease recurrence (odds ratio [OR], 5.48; 95% confidence interval [CI], 1.23 to 24.48; P = 0.03) as well as increased overall mortality (OR, 8.16; 95% CI, 1.72 to 38.63; P = 0.01). In conclusion, ENE is associated with increased overall axillary nodal burden, disease recurrence, and overall mortality.

Sentinel Lymph Node Biopsy is a Reliable Method for Lymph Node Evaluation in Neoadjuvant Chemotherapy-treated Patients with Breast Cancer

2014 ◽  
Vol 80 (2) ◽  
pp. 171-177 ◽  
Author(s):  
Starr B. Koslow ◽  
Rachel E. K. Eisenberg ◽  
Queenie Qiu ◽  
Zhengming Chen ◽  
Alexander Swistel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
False Negative ◽  
False Negative Rate ◽  
Axillary Lymph ◽  
Extranodal Extension ◽  
Node Biopsy ◽  
Negative Rate

Sentinel lymph node (SLN) mapping in patients with breast cancer treated with neoadjuvant chemotherapy has been debated by surgeons as a result of potential compromise of lymphatic drainage. Whether clinicopathologic variables traditionally associated with SLN positivity differ in patients who have been treated with neoadjuvant chemotherapy has not been well studied. Patients diagnosed with breast carcinoma who underwent neoadjuvant chemotherapy, definitive breast surgery, sentinel node biopsy (SNB), and axillary lymph node dissection (ALND) were retrospectively identified over a 75-month period. Clinicopathologic parameters including age, clinical tumor and node stage, neoadjuvant chemotherapy regimen, pathological tumor and node stage, lymphovascular invasion (LVI), SLN and non-SLN involvement, and extranodal extension were recorded. Ninety-seven patients met inclusion criteria. Ninety-eight per cent had successful SLN mapping. Eight patients with negative SLNs had positive ALND (false-negative rate, 8.3%). Clinicopathological variables associated with SLN status included clinical axillary status ( P = 0.038), pathologic tumor size, and nodal status and LVI ( P < 0.001). Extranodal extension was significantly associated with non-SLN status ( P = 0.004). In patients achieving a pathologic complete response (PCR), SNB remained feasible and accurate (false-negative rate, 11.6%). Successful SLN mapping in patients who have undergone neoadjuvant chemotherapy is highly accurate with a low false-negative rate even in patients who have a PCR.

Prognostic value of sentinel lymph node involvement in patients with breast cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 22213-22213
Author(s):  
M. Tobeña ◽  
M. Ruiz-Echarri ◽  
M. Ortega ◽  
E. Prats ◽  
E. Millastre ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Prognostic Value ◽  
Lymph Node Involvement ◽  
Node Involvement

Early Breast Cancer - Less Axillary Surgery?

Swiss Surgery ◽  
2000 ◽  
Vol 6 (3) ◽  
pp. 116-120 ◽  
Author(s):  
Gambazzi ◽  
Zuber ◽  
Oertli ◽  
Marti ◽  
Kocher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Early Breast Cancer ◽  
Axillary Surgery ◽  
Kaplan Meier

Kleine Mammakarzinome werden häufiger entdeckt. Die nodal positiven Fälle werden seltener. Die sentinel lymph node (SLN) Technik könnte die geeignete Methode sein, unnötige Axilladissektionen zu vermeiden. Wir untersuchten ein Kollektiv von Patientinnen mit pT1 Tumoren in Bezug auf Nodalstatus (pT1a,b und c), auf Axillarezidiv sowie auf das Gesamtüberleben. Von 1983 bis 1997 wurden konsekutiv 185 Frauen mit einem Mammakarzinom </= 20mm Durchmesser behandelt. Die Überlebensdaten nach Kaplan-Meier stützten sich auf eine Kohorte aus 117 Patientinnen mit einer medianen Nachsorge von mindestens sieben Jahren. Es fanden sich sieben Patientinnen mit einem pT1a Karzinom, 30 mit einem pT1b Karzinom und 148 mit einem pT1c Karzinom. Im Mittel wurden 16 axilläre Lymphknoten vom Pathologen gezählt. Der axilläre Lymphknotenbefall zeigte eine erwartete Abhängigkeit von der Tumorgrösse: Kein Axillabefall bei nur sieben pT1a, 10% befallene Lymphknoten bei pT1b und 30% bei pT1c Karzinomen. Kein einziges Axillarezidiv wurde während der Beobachtungszeit entdeckt. Das Gesamtüberleben nach zehn Jahren betrug für Patientinnen mit einem pT1a Karzinom 100%, 91% für pT1b und noch 74% für pT1c Karzinome. Die Screening Mammographie entdeckt vermehrt kleinere Mammakarzinome. Die pN+ Stadien nehmen ab. Hier müssen Nutzen und Risiko der Axilladissektion einander kritisch gegenübergestellt werden. Eine selektive Axilladissektion ermöglicht die sentinel lymph node (SLN) Methode, welche in Verbindung mit aufwendigeren histologischen Nachweismethoden den axillären Nodalstatus realistisch wiedergibt.

Sign in / Sign up

Export Citation Format

Share Document